Overview Dividends

(TMHC) Taylor Morn Home - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US87724P1066

Single-Family, Multi-Family, Master-Planned, Commercial, Build-To-Rent

Homebuilding
Market Cap in USD: 6,126m
IPO / Inception: 2013-04-10
Return 12m vs S&P 500: -21.2%

Dividends

Currently no dividends paid
Risk via 10d forecast
Volatility 34.1%
Value at Risk 5%th 52.8%
Relative Tail Risk -5.79%
Reward TTM
Sharpe Ratio -0.28
Alpha -21.40
CAGR/Max DD 0.96
Character TTM
Hurst Exponent 0.400
Beta 0.707
Beta Downside 0.416
Drawdowns 3y
Max DD 27.90%
Mean DD 9.57%
Median DD 8.05%

Description: TMHC Taylor Morn Home November 06, 2025

Taylor Morrison Home Corp. (NYSE: TMHC) is a U.S. land developer and homebuilder that designs, builds, and sells single- and multi-family detached and attached homes, plus lifestyle and master-planned communities. Its portfolio also includes multi-use projects (commercial, retail, and multifamily) under the Urban Form brand, financial and settlement services, and a build-to-rent operation (Yardly). The company markets homes under the Taylor Morrison, Darling Homes Collection, and Esplanade brands across 13 states, from Arizona to Washington.

Key operational metrics (FY 2023): revenue of $5.9 billion, 13,300 homes delivered, and an average selling price (ASP) of $447 k-about 4% above the industry median. Inventory stood at ≈ 3,200 units, giving a sell-through rate of roughly 70% in a market where mortgage rates have hovered near 7%, a primary driver of demand elasticity for homebuilders.

Given TMHC’s exposure to regional price differentials and its diversification into rent-to-own (Yardly) and mixed-use assets, a deeper quantitative view-such as inventory turnover, price-to-sales ratios, and sensitivity to interest-rate shifts-can be explored on the ValueRay platform.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (853.6m TTM) > 0 and > 6% of Revenue (6% = 502.7m TTM)
FCFTA 0.06 (>2.0%) and ΔFCFTA 5.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 77.90% (prev 81.08%; Δ -3.17pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.06 (>3.0%) and CFO 619.3m <= Net Income 853.6m (YES >=105%, WARN >=100%)
Net Debt (1.89b) to EBITDA (1.28b) ratio: 1.48 <= 3.0 (WARN <= 3.5)
Current Ratio 7.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (100.0m) change vs 12m ago -5.69% (target <= -2.0% for YES)
Gross Margin 23.96% (prev 24.45%; Δ -0.49pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 88.53% (prev 84.21%; Δ 4.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 30.59 (EBITDA TTM 1.28b / Interest Expense TTM 40.9m) >= 6 (WARN >= 3)

Altman Z'' 8.56

(A) 0.68 = (Total Current Assets 7.60b - Total Current Liabilities 1.07b) / Total Assets 9.63b
(B) 0.52 = Retained Earnings (Balance) 5.00b / Total Assets 9.63b
(C) 0.13 = EBIT TTM 1.25b / Avg Total Assets 9.46b
(D) 1.46 = Book Value of Equity 5.00b / Total Liabilities 3.43b
Total Rating: 8.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 67.92

1. Piotroski 6.0pt
2. FCF Yield 7.23%
3. FCF Margin 6.92%
4. Debt/Equity 0.37
5. Debt/Ebitda 1.48
6. ROIC - WACC (= 5.15)%
7. RoE 14.20%
8. Rev. Trend -0.91%
9. EPS Trend 11.86%

What is the price of TMHC shares?

As of December 12, 2025, the stock is trading at USD 62.06 with a total of 1,077,998 shares traded.
Over the past week, the price has changed by -3.89%, over one month by +4.28%, over three months by -10.95% and over the past year by -9.07%.

Is TMHC a buy, sell or hold?

Taylor Morn Home has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy TMHC.
  • Strong Buy: 4
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the TMHC price?

Issuer Target Up/Down from current
Wallstreet Target Price 73.6 18.6%
Analysts Target Price 73.6 18.6%
ValueRay Target Price 69.3 11.6%

TMHC Fundamental Data Overview December 02, 2025

Market Cap USD = 6.13b (6.13b USD * 1.0 USD.USD)
P/E Trailing = 7.553
P/E Forward = 10.4493
P/S = 0.7312
P/B = 0.9907
P/EG = 1.511
Beta = 1.578
Revenue TTM = 8.38b USD
EBIT TTM = 1.25b USD
EBITDA TTM = 1.28b USD
Long Term Debt = 2.19b USD (from longTermDebt, last quarter)
Short Term Debt = 73.0m USD (from shortTermDebt, last quarter)
Debt = 2.26b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.89b USD (from netDebt column, last quarter)
Enterprise Value = 8.02b USD (6.13b + Debt 2.26b - CCE 370.6m)
Interest Coverage Ratio = 30.59 (Ebit TTM 1.25b / Interest Expense TTM 40.9m)
FCF Yield = 7.23% (FCF TTM 580.0m / Enterprise Value 8.02b)
FCF Margin = 6.92% (FCF TTM 580.0m / Revenue TTM 8.38b)
Net Margin = 10.19% (Net Income TTM 853.6m / Revenue TTM 8.38b)
Gross Margin = 23.96% ((Revenue TTM 8.38b - Cost of Revenue TTM 6.37b) / Revenue TTM)
Gross Margin QoQ = 22.74% (prev 23.56%)
Tobins Q-Ratio = 0.83 (Enterprise Value 8.02b / Total Assets 9.63b)
Interest Expense / Debt = 0.56% (Interest Expense 12.8m / Debt 2.26b)
Taxrate = 24.94% (67.9m / 272.4m)
NOPAT = 939.9m (EBIT 1.25b * (1 - 24.94%))
Current Ratio = 7.09 (Total Current Assets 7.60b / Total Current Liabilities 1.07b)
Debt / Equity = 0.37 (Debt 2.26b / totalStockholderEquity, last quarter 6.18b)
Debt / EBITDA = 1.48 (Net Debt 1.89b / EBITDA 1.28b)
Debt / FCF = 3.26 (Net Debt 1.89b / FCF TTM 580.0m)
Total Stockholder Equity = 6.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.87% (Net Income 853.6m / Total Assets 9.63b)
RoE = 14.20% (Net Income TTM 853.6m / Total Stockholder Equity 6.01b)
RoCE = 15.27% (EBIT 1.25b / Capital Employed (Equity 6.01b + L.T.Debt 2.19b))
RoIC = 11.55% (NOPAT 939.9m / Invested Capital 8.13b)
WACC = 6.41% (E(6.13b)/V(8.39b) * Re(8.62%) + D(2.26b)/V(8.39b) * Rd(0.56%) * (1-Tc(0.25)))
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.18%
[DCF Debug] Terminal Value 76.10% ; FCFE base≈356.0m ; Y1≈353.4m ; Y5≈369.4m
Fair Price DCF = 60.21 (DCF Value 5.88b / Shares Outstanding 97.7m; 5y FCF grow -1.47% → 3.0% )
EPS Correlation: 11.86 | EPS CAGR: -0.99% | SUE: 1.14 | # QB: 1
Revenue Correlation: -0.91 | Revenue CAGR: -4.65% | SUE: 0.65 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.13 | Chg30d=-0.167 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=6.61 | Chg30d=-0.864 | Revisions Net=-4 | Growth EPS=-15.8% | Growth Revenue=-11.3%

Additional Sources for TMHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle